• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Tumor Mutation Burden May Be Predictive of Depression in Patients With Lung Cancer

Video

Tumor mutation burden may be an independent predictor of developing depression in patients with lung cancer, according to Dr. Daniel McFarland.

Tumor mutation burden (TMB) is an independent predictor of inflammation that may be a predictive marker of developing depression in patients with lung cancer, according to Dr. Daniel McFarland.

“What tumor mutation burden is, essentially, is just a marker of how many mutations are in a person’s cancer,” McFarland, who is from the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering, explained. “What TMB is taking advantage of is our body’s innate immune system that responds to cancer as a foreign thing.” TMB up-regulates inflammation and fights against the cancer, which is fundamentally what immunotherapy does in patients with lung cancer, he added.

“At the same time there is a lot of data to say that inflammation is predictive of developing depression,” said McFarland. “The idea behind this study was because you have TMB as an up-regulator of inflammation around cancer, does that inflammation, which is also associated with depression, lead to depression in this scenario of people who have cancer?”

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, McFarland discussed the study findings and explains the link between a high tumor mutation burden, inflammation and developing depression in patients with both small cell and non-small cell lung cancer.

Related Videos
Catrina Crutcher in an interview with CURE
Dr. Ged in an interview with CURE at the 2023 KCRS
Dr. Toni Choueiri in an interview with CURE at the 2023 KCRS
Dr. Hannan in an interview with CURE at the KCRS conference
Jennifer King from the GO2 Foundation for Lung Cancer in an interview with CURE
Myelofibrosis Panel
Dr. John O. Mascarenhas
Related Content